Orthofix shares plunge as Q2 results indefinitely delayed
This article was originally published in Clinica
Executive Summary
New Orthofix International CEO Brad Mason now has even more on his plate after the firm sparked investor panic by indefinitely postponing its second-quarter results. The company’s share price dropped 16% to close at $22.94 on 30 July, the day after the announcement – this is also a two-year low for its stock.